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December 8, 2009:2337–410 years of experience with HCM, and countless patients who
ave taken antibiotics for that purpose.
It is obvious to us that following the most recent AHA
ecommendations and withholding antibiotics from patients with
CM will unavoidably have the effect of unnecessarily creating
everal new cases of infective endocarditis each year. We are at a
oss to understand how these AHA recommendations (2), which
e believe should be revised, are in the best interests of the HCM
atient population.
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e rely on guidelines. When large amounts of data exist, we rely
n expert summaries to distill the data and to make evidence-based
ecommendations. When data are more scarce, we rely on experts
o thoughtfully weigh the existing data along with their own
xperience, balancing risks and benefits, and make recommenda-
ions in the best interest of patient welfare.
It might be said too often, or might be said not often enough,
hat guidelines are . . . only guidelines. It remains imperative, espe-
ially when data are scarce, to understand the nature of guideline
ecommendations, including the presence or absence of data to
upport them. Ultimately, the savvy clinician should help his or her
atients individually weigh the relative risks and benefits of any
iagnostic test, or any therapeutic or prophylactic intervention.
his author thanks Drs. Maron and Lever for their discussion
egarding my paper (1) and for adding their voices to those of other
hysicians who, having cared for patients at risk of or suffering
rom endocarditis, raise concern about the new antibiotic prophy-
axis guidelines (2), ask whether they represent the best balance of
isk versus benefit, and ask whether these recommendations are the
ost likely means to adequately protect our patients (3–5).
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tent Overexpansion
nd Myocardial No-Reflow
arly revascularization of the infarct-related artery by primary
ercutaneous coronary intervention has become the mainstay of
herapy, especially in ST-segment elevation myocardial infarction.hen performed early in the course of acute myocardial infarction,
